The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

Jean-Luc Belingard net worth and biography

Jean-Luc Belingard Biography and Net Worth

Director of Laboratory Co. of America

Jean-Luc Bélingard has served as a director of the Company since April 28, 1995. Mr. Bélingard currently serves as Operating Advisor to Clayton, Dubilier & Rice, a private equity investment firm, since October 2019. From 2011 to December 2017, Mr. Bélingard served as Chairman and CEO of bioMérieux (Président Directeur Général), the worldwide leader of the IVD microbiology segment and a non-US public company. Mr. Bélingard continues to serve on the board of directors of bioMérieux and as Vice President of Institut Mérieux. Mr. Bélingard retired as Chairman and Chief Executive Officer of Ipsen SA, a diversified French healthcare holding company, on November 22, 2010. He had served in that position since 2002. Prior to this position, Mr. Bélingard was Chief Executive Officer from 1999 to 2001 of bioMérieux-Pierre Fabre, a diversified French healthcare holding company, where his responsibilities included the management of that company’s worldwide pharmaceutical and cosmetic business. From 1990 to 1999, Mr. Bélingard was Chief Executive Officer of Roche Diagnostics and a member of the Hoffman La Roche group Executive Committee. Mr. Bélingard is a director of Lupin Limited (India), a non-US public company. Mr. Belingard is also a director at Transgene SA, an Institut Mérieux company. Mr. Bélingard has served on the board of Laboratoire Pierre Fabre S.A. (France) since 2013, which is owned by The Pierre Fabre Foundation, a government-recognized public organization. Mr. Bélingard is also a member of the Bill and Melinda Gates Foundation CEO Roundtable and has served on the Novo Advisory Group of Novo Holdings, which is wholly owned by the Novo Nordisk Foundation, since 1998. Mr. Belingard was Chairman of “FEFIS,” the French Federation of Health Industries (Fédération Française des Industries de Santé) from 2016 to December 2019, and, from January 2017 until 2019 he was a member of the Conseil National de l’Industrie (C.N.I.) chaired by the French government.

What is Jean-Luc Belingard's net worth?: The estimated net worth of Jean-Luc Belingard is at least $3.60 million as of May 3rd, 2021. Mr. Belingard owns 18,169 shares of Laboratory Co. of America stock worth more than $3,604,730 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Belingard may own. Learn More about Jean-Luc Belingard's net worth.
How do I contact Jean-Luc Belingard?: The corporate mailing address for Mr. Belingard and other Laboratory Co. of America executives is 358 South Main Street, BURLINGTON NC, 27215. Laboratory Co. of America can also be reached via phone at (336) 229-1127 and via email at [email protected]. Learn More on Jean-Luc Belingard's contact information.
Has Jean-Luc Belingard been buying or selling shares of Laboratory Co. of America?: Jean-Luc Belingard has not been actively trading shares of Laboratory Co. of America during the past quarter. Most recently, Jean-Luc Belingard sold 2,600 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $269.16, for a transaction totalling $699,816.00. Following the completion of the sale, the director now directly owns 18,169 shares of the company's stock, valued at $4,890,368.04. Learn More on Jean-Luc Belingard's trading history.
Who are Laboratory Co. of America's active insiders?: Laboratory Co. of America's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Brian Caveney (EVP), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Laboratory Co. of America's active insiders.
Are insiders buying or selling shares of Laboratory Co. of America?: During the last year, insiders at the medical research company sold shares 14 times. They sold a total of 66,701 shares worth more than $14,419,280.01. The most recent insider tranaction occured on April, 1st when COO Mark S Schroeder sold 6,477 shares worth more than $1,407,387.33. Insiders at Laboratory Co. of America own 0.9% of the company. Learn More about insider trades at Laboratory Co. of America.
Information on this page was last updated on 4/1/2024.

Jean-Luc Belingard Insider Trading History at Laboratory Co. of America

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/3/2021	Sell	2,600	$269.16	$699,816.00	18,169
2/19/2020	Sell	26,479	$189.76	$5,024,655.04	41,161
5/9/2017	Sell	992	$142.19	$141,052.48	32,935
2/25/2016	Sell	1,296	$109.74	$142,223.04	30,722
4/29/2015	Sell	1,542	$123.10	$189,820.20
5/8/2013	Sell	2,536	$92.88	$235,543.68

Jean-Luc Belingard Buying and Selling Activity at Laboratory Co. of America

Laboratory Co. of America Company Overview

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Today's Range

Now: $198.40

$197.01

$200.15

50 Day Range

MA: $212.06

$198.35

$219.16

2 Week Range

Now: $198.40

$174.20

$234.09

Volume

931,285 shs

Average Volume

758,681 shs

Market Capitalization

$16.69 billion

P/E Ratio

42.48

Dividend Yield

1.38%

Beta

1.01

Move Your Money Before May 22

From Stansberry Research | Ad